HALEOSLABS · Health Care · 2026-08-07

Haleos Labs Ltd

MARKET: BULL TOPPING · 2026-08-07

₹1,457.4

+1.30% today

₹441 Cr · Micro cap

About this companyHealth Care· Pharmaceuticals

Expand ▾

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.

Visit company website →

P/E (TTM)

24.8

Forward —

Earnings Growth (YoY)

+21.1%

Revenue +12.0%

Dividend Yield

0.09%

P/B 2.4

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 37

1w13w26w

Week 37 — mature, watch for distribution

How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.23x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

MA20 rolling over · -1.6% vs MA50 -1.2%

Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.

Sector

Health Care

↑ Building

Stage 2%

51.6%

20d Δ

+1.6pp

1M return

+3.1%

3M return

+11.6%

Sector Stage-2 % · last 20 days

Sector has 79 Stage 2 leaders. See Health Care Stage 2 →

Industry

Pharmaceuticals

→ Flat

Stage 2%

50.5%

20d Δ

+0.5pp

1M return

+1.9%

3M return

+11.7%

Industry Stage-2 % · last 20 days

Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →

Price + Volume Chart

Loading price chart…

Stage Cycle Timeline2025-11-17 → 2026-08-07

S? 38w

2025-11-172026-08-07

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 38w current

Total tracked: 38 weeks across 1 stage run.

-5.8%

-11.3%

+15.3%

YTD

+16.7%

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-08-07S—

Wk 37 · Vol —x

2026-08-06S—

Wk 37 · Vol —x

2026-08-05S—

Wk 37 · Vol —x

2026-08-04S—

Wk 36 · Vol —x

2026-08-03S—

Wk 36 · Vol —x

2026-07-31S—

Wk 36 · Vol —x

2026-07-30S—

Wk 36 · Vol —x

2026-07-29S—

Wk 36 · Vol —x

2026-07-28S—

Wk 35 · Vol —x

2026-07-27S—

Wk 35 · Vol —x

2026-07-24S—

Wk 35 · Vol —x

2026-07-23S—

Wk 35 · Vol —x

Sector Peers — Stage 2All →

DIVISLAB

wk 12 · -3.6% from hi

8.5

LAURUSLABS

wk 16 · -0.3% from hi

8.4

PPLPHARMA

wk 4 · 0.0% from hi

8.2

LALPATHLAB

wk 9 · 0.0% from hi

7.9

SHILPAMED

wk 13 · 0.0% from hi

7.8

Moving averages & range

50 DMA

₹1,496.5

200 DMA

—

52W High

—

52W Low

—

5D Low

₹1,427.7

Resistance levels (recent highs)

20d High

₹1,623.6

60d High

₹1,686.2

120d High

₹1,690.1

250d High

—

Next resistance

+11.4%

to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.